J
Jing Liu
Researcher at China Medical University (PRC)
Publications - 88
Citations - 2429
Jing Liu is an academic researcher from China Medical University (PRC). The author has contributed to research in topics: Cancer cell & Apoptosis. The author has an hindex of 26, co-authored 80 publications receiving 1997 citations.
Papers
More filters
Journal ArticleDOI
Low-Dose Endothelial Monocyte-Activating Polypeptide-II Increases Blood-Tumor Barrier Permeability by Activating the RhoA/ROCK/PI3K Signaling Pathway.
TL;DR: It is demonstrated that low-dose EMAP-II can increase BTB permeability by activating the RhoA/ROCK/PI3K signaling pathway.
Journal ArticleDOI
The Role of HIV-1 in Affecting the Proliferation Ability of HPCs Derived From BM.
Xiaolin Guo,Sijia He,Xiaoyi Lv,Haibo Ding,Sha Li,Jing Kang,Jing Liu,Chaolong Qin,Wenqing Geng,Yongjun Jiang,Hong Shang +10 more
TL;DR: It is demonstrated that after antiretroviral therapy, CD4+ T-cell recovery and HPCs proliferation ability are correlated, which has implications in understanding whether bone marrow-derived H PCs can supplement for the loss of CD4- T lymphocytes during HIV-1 infection.
Journal ArticleDOI
Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer
Na Song,Xiujuan Qu,Shizhou Liu,Simeng Zhang,Jing Liu,Jinglei Qu,Huachuan Zheng,Yunpeng Liu,Xiaofang Che +8 more
TL;DR: It was demonstrated that combination treatment exerted increased viability inhibition and apoptosis enhancement in mutant and wild type RAS colon cancer cells, suggesting combinational inhibition of MET and SRC may be a promising strategy for the treatment of CRC.
Journal ArticleDOI
Alteration of inhibitory and activating NK cell receptor expression on NK cells in HIV-infected Chinese.
Yongjun Jiang,Lei He,Huan Chen,Tristan Bice,Zining Zhang,Jing Liu,Haibo Ding,Xiaoxu Han,Hong Shang +8 more
TL;DR: The results indicate that the distinct alteration of activating and inhibitory NKR expression on NK cells and its subsets occurred during HIV progression, which may explain the impaired NK cell immunity in HIV infected individuals.
Journal ArticleDOI
Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.
Lingyun Zhang,Yuee Teng,Ye Zhang,Jing Liu,Ling Xu,Jinglei Qu,Kezuo Hou,Yunpeng Liu,Xiujuan Qu +8 more
TL;DR: The theory that PS-341 treatment may be unsuitable for RANK-positive breast cancer patients is supported for the first time as the effect of the proteasome inhibitor bortezomib on RANKL-induced MDA-MB-231 breast cancer cell migration is explored.